Hormonal Disorder Articles & Analysis: Older
3 articles found
The core programs include: Octreotide for acromegaly or neuroendocrine tumors in the GI tract. Acromegaly is a hormonal disorder that develops when the pituitary gland produces too much growth hormone during adulthood. TNF-alpha inhibitors for psoriatic arthritis. Parathyroid hormone for osteoporosis. Human growth ...
Octreotide (also known as Sandostatin) is a man-made, synthetic version of the natural hormone somatostatin. It is normally delivered through injection and behaves similarly to somatostatin. Octreotide is often using with NETS as it slows down the production of hormones which helps to control symptoms of carcinoid syndrome. It ultimately slows down the growth of ...
Related Link: The Daily Biotech Pulse: Erytech Jumps On Fast Track Designation, GlaxoSmithKline FDA Nod, Alnylam's Clinical Collaboration, 4 IPOs Rani's Pipeline: Rani has a candidate codenamed RT-10 in Phase 1 development for acromegaly, a hormonal disorder. The company has five preclinical compounds evaluated for different indications. ...